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Background: evidence on the effectiveness and usage of long-term anticoagulant therapy after acute thromboembolic limb
ischaemia is very sparse. This study correlated medical events with administration of warfarin.
Method: during a three-month audit in 1996, 287 patients with embolism or thrombosis in situ survived for 30 days,
and 214 (75%) were reviewed by questionnaires returned from clinicians throughout the United Kingdom. Minimum
follow-up was two years.
Results: thirty-five per cent had died. Recurrent acute limb ischaemia was reported in 11%, arterial intervention in
11%, and major amputation in 12%. Warfarin was given initially to 57% patients, but at follow-up only 43% were still
taking warfarin (p<0.05); reasons for stopping anticoagulation were often unknown. Recurrent limb ischaemia was less
common in patients given warfarin initially (7% versus 17%) and still taking warfarin (3% versus 19%) – p<0.05.
Amputation was also less common in patients given warfarin initially (5% versus 21%) and still on warfarin (3% versus
21%) – p<0.05.
Conclusion: long-term oral anticoagulation was associated with reduced risk of recurrent limb ischaemia and amputation,
but more research is needed to define the benefits and risks, especially for thrombosis in situ. Clinicians should give clear
advice about anticoagulation when patients are discharged from hospital.
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Introduction (surviving longer than 30 days after their acute leg
ischaemia) after a minimum follow-up interval of two
In 1996 the Vascular Surgical Society of Great Britain years.
The use of long-term anticoagulants after acuteand Ireland (VSSGBI) undertook a survey designed to
include all patients admitted to hospital with acute thromboembolic limb ischaemia in patients is in-
consistent, and little is known about current practice.leg ischaemia during the first quarter of the year (1st
January to 31st March).1 A total of 539 episodes was There is evidence of benefit from long-term anti-
coagulation in patients with atrial fibrillation,2–4 butreported in 474 patients, and each was the subject of
a detailed questionnaire. Not all hospitals reported not all such patients are anticoagulated after suffering
acute ischaemia, and we do not know how many ofcases, but a supplementary audit of patients admitted
to non-contributing hospitals showed no important those started on anticoagulants continue with them.
For patients with thrombosis in situ there is littledifferences in types of treatment, limb salvage, or
survival. Hospitals in the Republic of Ireland did not evidence to inform clinicians about the effect of long-
term anticoagulants, and practice seems to vary. Aparticipate, and data therefore reflected practice in the
United Kingdom only. particular aspect of this follow-up study was enquiry
about the use, duration of administration, and theOf the 539 episodes of acute ischaemia 40% (206)
were thought to be due to thrombosis in native vessels, effects of oral anticoagulants following acute leg isch-
aemia in the United Kingdom.and 38% (191) due to embolism – a total of 78% (397)
due to thromboembolism. The aim of the present study
was to find out what had happened to these patients
Patients and Methods
* Please address all correspondence to: W. B. Campbell, Vascular
Surgical Society of Great Britain and Ireland, at the Royal College From the original VSSGBI survey, patients were iden-of Surgeons of England, 35–43 Lincolns Inn Fields, London WC2A
3PN, U.K. tified in whom a working diagnosis of thrombosis or
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Table 1. Documented causes of death for the 71/202 patientsembolism had been made, and who had survived
known to have died during the follow-up interval.the 30-day period of scrutiny required by that study,
‘‘Thromboembolic’’ 20following their last episode of acute leg ischaemia.
Myocardial infarct 11Patients with graft or angioplasty site occlusions, with
Limb ischaemia 4iatrogenic or traumatic acute ischaemia, and with Stroke 3
Mesenteric infarct 2thrombosed aneurysms were excluded.
Cardiac failure 5For each patient, a questionnaire was sent, with the
Pulmonary 9patient’s hospital number, date of birth, sex and age; Malignant disease 10
Sepsis 5and together with an explanatory letter. The following
Ruptured aortic aneurysm 2questions were asked:
Diabetic ketoacidosis 1
Not known 19Following the episode of acute ischaemia in 1996, has
the patient had (If Yes, please give details, with dates
if known – all answers Yes/No): embolism survived 30 days, and details were returned
(a) further acute limb ischaemia; for 214 – a response rate of 75%. Exactly half (107)
(b) further arterial reconstruction; were male, and the age range was 21–96 (median 74)
(c) further lysis; years.
(d) amputation of the affected leg; Thirty-five per cent (71/102) of patients had died,
(e) stroke; and causes of death are shown in Table 1 (outcome
(f) myocardial infarction; unknown for 19 patients). Almost half of the known
(g) other major events. causes were thromboembolic (38%) or cardiac failure
(10%), while malignant disease (19%) and pulmonaryAfter the episode of acute ischaemia in 1996, did the
disease (18%) accounted for the majority of the re-patient receive warfarin?
mainder.Is the patient still taking warfarin?
Further acute limb ischaemia was reported in 11%
If warfarin was stopped, when and why? (21 of the 189 with definite information), vascular
Has the patient died? If so, date and cause of death. intervention in 11% (11 surgical operations, seven
angioplasties, and two thrombolytic infusions), andThe questionnaire was purposely limited to a single
amputation of the leg had been required (after 30side of A4 paper, to encourage completion. When
days) in 11% (21 of 189). Further analysis of thesequestionnaires were not returned, one of the authors
patients revealed that among the 21 patients with(BMFR) wrote again to hospitals, and subsequently
recurrent acute ischaemia ten had vascular inter-telephoned consultants.
vention (six surgery, four angioplasty, and two lysis –A proportion of patients had been lost to follow-
one had surgery plus angioplasty, and one surgeryup. This explained some of the questionnaires which
plus lysis), and 13 had amputation. The other patientswere not returned (but how many is unknown), and
with interventions for limb ischaemia were four havingresulted in responses of ‘‘Not known’’ to some ques-
surgical reconstruction (followed by one amputation),tions. Throughout the results, denominators less than
four having angioplasty (no amputation) and twothe total number of returned questionnaires are due
having lysis (both amputated). In addition, six patientsin part to this incomplete follow-up, and in part to
had amputations without preceding acute ischaemiainformation which was simply missing for a variety
or vascular intervention.of reasons. All statistical comparisons were by Chi-
Reported medical events (presumed non-fatal) weresquared analysis, with Yates’ correction for small num-
myocardial infarction in 4% (7/173), stroke in 3% (5/bers.
173), and other major medical events in 24% (40/171)The questionnaires were sent out during April 1998
(Table 2). The details which were reported suggestedand the last responses were received in June 1998,
that knowledge of myocardial infarction and strokegiving a follow-up interval of 24–30 months after the
(both as fatal and non-fatal events) was indequate toepisodes of acute ischaemia.
use these as outcome measures by which to judge
any effects of warfarin therapy. Recurrent acute limb
ischaemia and amputation were therefore used as
outcome measures for comparison of patients re-Results
ceiving, or not receiving, warfarin (both usually re-
quire hospital admission, and details should thereforeTwo hundred and eighty-seven patients with a dia-
gnosis of acute leg ischaemia due to thrombosis or have been available in most cases).
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Table 2. ‘‘Other major events’’ (excluding myocardial infarction Table 4. Incidence of further acute limb ischaemia among patients
who had been given warfarin at any time, compared with thoseand stroke): details given in the comments added to questionnaire
responses (accounting for 34 of the cases reported to have had who had not received warfarin. Note that responses about recurrent
limb ischaemia were missing in 8 cases.‘‘other major events’’). Information had been gleaned from the
hospital notes, and events dealt with only in primary care are
unlikely to have been reported. Recurrent acute limb
ischaemia
Cardiovascular 11
Cardiac failure 3 Yes No
Coronary bypass graft 2
Cardioversion required 2 Given warfarin initially 7/107 (7%) 13/77 (17%) p<0.05




Bronchus+colon 1 still taking warfarin (Table 4). When patients wereBronchus 1
subdivided into those thought to have had emboli,Kidney 1
Bladder 1 and those who had thrombosis in situ, the percentages
Prostate 1 who had recurrent limb ischaemia were still nu-Gastrointestinal bleeding 4
merically lower among those on warfarin, but dif-Toe amputations 3
Severe leg ulcers 1 ferences failed to reach statistical significance (Table
Miscellaneous 10 4). Numbers of patients with recurrent acute ischaemiaDiabetic ketoacidosis 2
were small – four or less in each subgroup – exceptPneumonia 2
Myelofibrosis 1 for patients with thrombosis who were not given
Parathyroidectomy 1 warfarin (13/67). Further subdivision into those withFractured femur 1
and without atrial fibrillation produced still smallerPerforated peptic ulcer 1
Falls and confusion 1 numbers of events in each group, and differences again
Total 34 failed to reach significance.
Amputation was significantly less common among
those who had been given warfarin initially – 5% (5/
Table 3. Reasons given for discontinuation of warfarin therapy 104) – than those who had not – 21% (16/78) (p<0.05).in 18 patients.
A similar advantage was seen for patients still taking
Bleeding complications 4 warfarin – 3% (2/62) versus 21% (17/81) respectively
3 gastrointestinal (p<0.05).1 epistaxis
There was no association between initial ad-‘‘Age and frailty’’ 3
Patient preference 2 ministration of warfarin and death during the follow-
Planned limited course 2 up interval – mortality 31% (34/108) on warfarinMiscellaneous 7
versus 35% (29/83) not on warfarin. The way in whichPrior to aortobifemoral graft
Prior to arteriography questions had been asked and answered were im-
Having thrombolysis possible to interpret.Foot not viable
Started on aspirin
Myeloproliferative disorder
Stopped by General Practitioner
DiscussionTotal 18
Before discussing the implications of this study, the
completeness and methods of interpreting the dataAfter their initial episode of acute leg ischaemia 57%
(110/194) patients were given warfarin, but sig- need to be considered. We recognised at the outset
that many details might be difficult to obtain aboutnificantly fewer – 43% (66/152) – were still taking
warfarin when information was provided for the ques- elderly patients for whom long-term hospital follow-
up was not routine, who might well be treated fortionnaire (p<0.05). Information about discontinuation
of therapy was available in only 18 cases: warfarin major medical events in primary care only, and many
of whom might die outside hospital during the two-was stopped after intervals of 1–22 (median 6) months
in these patients, and the reasons are shown in Table year follow-up interval. It seemed likely that most
patients who suffered recurrent acute limb ischaemia3.
The incidence of recurrent acute limb ischaemia was (and definitely those having amputation) would have
been re-admitted to hospital, while information mightsignificantly lower with warfarin therapy (p<0.05),
both for patients initially on warfarin, and for those well not be returned about those having other medical
Eur J Vasc Endovasc Surg Vol 19, February 2000
W. B. Campbell et al.172
events, or dying outside hospital. On the basis of these reasonably be considered to have a high ‘‘inherent
risk’’ of further embolic events, but evidence of theassumptions, it seemed reasonable to use recurrent
acute limb ischaemia and amputation as the main effectiveness of long-term anticoagulation in this popu-
lation is surprisingly sparse. The one randomisedoutcome measures for further limb ischaemia, while
the response rate of 75% was considered an adequate study, by Jivegard et al.,10 examined warfarin against
placebo for the first 30 days only, and showed abasis from which to draw general conclusions.
Our observed mortality rate of 35% is not surprising statistically insignificant trend towards patient sur-
vival without an amputation following embolectomyin an elderly group of patients with cardiovascular
disease, and has been observed in follow-up studies when warfarin was used. Takolander et al.6 observed
a significant reduction in amputation during the firstafter embolectomy.5,6 Mortality is higher in patients
with cardiac problems, and particularly those with month after embolectomy in a non-randomised, retro-
spective series. The few long-term studies of warfarinatrial fibrillation.7,8 Some reports5,6,9 have described
significantly lower mortality with oral anticoagulant treatment after embolectomy have also been non-ran-
domised and uncontrolled, and their conclusions havetherapy than without, although much of this difference
was accounted for by early deaths. The present study varied. For example, Elliott et al.5 observed a lower
incidence of recurrent emboli among 225 patients fol-has shown no difference in overall mortality between
30 days and two years associated with initial warfarin lowed for a mean of three years. By contrast, Silvers
et al.11 found no apparent advantage from warfarintherapy (although it proved impossible to correlate
responses to the question ‘‘Is the patient still taking therapy with regard to the incidence of recurrent
embolism in 106 patients followed for an unspecifiedwarfarin?’’ with death during follow-up interval).
This study has shown a significantly lower incidence period. Other smaller studies have also produced con-
flicting results.9–12of recurrent limb ischaemia and amputation in patients
treated with warfarin – both for initial administration Evidence on the role of long-term anticoagulants
after thrombolysis for acute arterial thrombosis is evenof warfarin and continued treatment to the time of
follow-up. Although the figures did not reach stat- more elusive,13 with few published observations and
no controlled studies. Those who have claimed toistical significance in subgroup analyses of those with
embolism and with thrombosis, it is not unreasonable show that anticoagulants are unhelpful in the long
term have provided no convincing data,14,15 and war-to argue that the event rate was low, and the trend
strongly suggested a benefit from warfarin, especially farin is commonly used after lysis when no correctable
underlying cause is found16 or in patients who arein patients with embolism. This concurs with pub-
lished evidence showing benefit from warfarin in large hypercoagulable.15 When bypass grafting is done, then
there is some evidence of enhanced patency with long-randomised studies of patients with atrial fibrillation.
Petersen et al.3 compared aspirin, warfarin, and placebo term anticoagulants.18,19
Reported adverse effects of warfarin were un-in a prospective randomised study (aspirin and
placebo blind, but warfarin openly) and found a sig- common in this study, with only four instances of
haemorrhage leading to cessation of treatment. Es-nificantly lower incidence of thromboembolism with
warfarin (5/335) than with aspirin (20/336) or placebo timates of the frequency of bleeding vary, but detailed
analysis of bleeding complications in a large controlled(21/336) during a two-year follow-up interval. More
recently, the Stroke Prevention in Atrial Fibrillation study of long-term oral anticoagulant prophylaxis after
myocardial infarction showed a low incidence, whichInvestigators4 have reported a study of warfarin
against aspirin in 715 patients during a 3–4-year follow- did not materially affect the benefit of anticoagulation
in preventing recurrent infarction.20 A low rate ofup. The occurrence of ischaemic stroke and systemic
embolism was reduced by warfarin treatment from haemorrhagic problems depends on good control of
anticoagulation, and likely patient compliance should1.9% to 1.3% per year in younger patients (less than
75 years), and from 4.8% to 3.6% in older patients. In be taken into account when planning long-term war-
farin administration.view of the significant but small reduction in risk the
authors recommended selective use of warfarin, taking It has been suggested that selection of patients for
anticoagulation should routinely be informed by car-into account each patient’s age and ‘‘inherent risk
of thromboembolism’’. Work by Lodder et al.2 also diological advice,21 but for the majority in whom the
likely cause is atrial fibrillation it is difficult to see asuggested only modest benefit from warfarin treat-
ment, when used long-term in patients with atrial real advantage from medical involvement apart from
ensuring good control of cardiac rhythm and rate. Infibrillation who had already suffered a stroke.
Patients who have suffered embolism to a limb could a series of 47 patients having echocardiography after
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